Dr. Reddys Laboratories Ltd.

Dr. Reddy’s Laboratories has launched Duloxetine Delayed-Release Capsules USP 20 mg, 30 mg and 60 mg, a therapeutic equivalent generic version of CYMBALTA (Duloxetine Delayed-Release Capsules) in the US market on June 26, 2014. The pharma major’s Duloxetine Delayed-Release Capsules USP 20 mg, 30 mg and 60 mg are available in several bottle counts.

The pharma major’s ANDA is approved by the United States Food & Drug Administration (USFDA). The CYMBALTA brand and generic had US sales of approximately $5.04 Billion MAT for the most recent twelve months ending in April 2014 according to IMS Health.

Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.